

Special Issue

Pediatric Liver Tumors (Hepatoblastoma and Hepatocellular Carcinoma)

Message from the Guest Editors

Pediatric liver tumors, including hepatoblastomas (HB) and pediatric hepatocellular carcinomas (HCC), are rare but devastating malignancies, the incidence of which has been increasing over the past few decades. The pathogenesis of these tumors is only partially known, with HBs having an extremely low mutational burden, with beta catenin mutations and Wnt pathway dysregulation being the most frequent molecular abnormalities. Pediatric HCC may develop against the background of specific hereditary diseases, including tyrosinemia and progressive familial intrahepatic cholestasis or viral infections, or may not have any predisposing factors. This current Special Issue of *Cancers* aims to collect a series of original and review articles on pediatric liver tumors from all angles of clinical and basic research, sharing both increases in the understanding of the pathogenesis of these tumors as well translational and clinical findings that may have direct effects on patient management.

Guest Editors

Dr. Ronald de Krijger

Dr. Carolina Armengol

Prof. Dr. Sarangarajan Ranganathan

Deadline for manuscript submissions

closed (31 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/124924

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)